Fulcrum Therapeutics
(NASDAQ) FULC
Fulcrum Therapeutics Financials at a Glance
Market Cap
$446.22M
Revenue (TTM)
$0.00
Net Income (TTM)
$74.88M
EPS (TTM)
$-1.18
P/E Ratio
-5.67
Dividend
$0.00
Beta (Volatility)
1.34 (Average)
Dividend
$0.00
Beta (Volatility)
1.34 (Average)
Price
$6.97
Volume
20,930
Open
$6.83
Price
$6.97
Volume
20,930
Open
$6.83
Previous Close
$6.97
Daily Range
$6.81 - $7.14
52-Week Range
$2.31 - $15.74
Dividend
$0.00
Beta (Volatility)
1.34 (Average)
Price
$6.97
Volume
20,930
Open
$6.83
Previous Close
$6.97
Daily Range
$6.81 - $7.14
52-Week Range
$2.31 - $15.74
FULC News
FULC: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Fulcrum Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
55
CEO
Alexander C. Sapir, MBA
Website
www.fulcrumtx.comHeadquarters
Cambridge, MA 02139, US
FULC Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-25%
Return on Capital
-24%
Return on Assets
-20%
Earnings Yield
-17.64%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$446.22M
Shares Outstanding
66.60M
Volume
20.93K
Short Interest
0.00%
Avg. Volume
1.01M
Financials (TTM)
Gross Profit
$1.39M
Operating Income
$84.77M
EBITDA
$73.49M
Operating Cash Flow
$60.06M
Capital Expenditure
$314.00K
Free Cash Flow
$60.38M
Cash & ST Invst.
$352.31M
Total Debt
$6.44M
Fulcrum Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$300.00K
+181.3%
Gross Margin
0.00%
N/A
Market Cap
$446.22M
N/A
Market Cap/Employee
$9.92M
N/A
Employees
45
N/A
Net Income
$20.33M
-22.7%
EBITDA
$19.99M
-23.4%
Quarterly Fundamentals
Net Cash
$345.86M
+48.8%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
N/A
Long Term Debt
$4.04M
-37.3%
Short Term Debt
$2.40M
+10.0%
Return on Assets
-20.44%
N/A
Return on Invested Capital
-24.00%
N/A
Free Cash Flow
$16.96M
+0.2%
Operating Cash Flow
$16.80M
-0.2%